

**Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab)
Recombinant Antibody
Catalog # APR10379****Specification****Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	O14788
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.16 KDa

Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) - Additional Information**Target/Specificity**

TNFSF11 / RANKL / CD254

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) - Protein Information**Name** TNFSF11**Synonyms** OPGL, RANKL, TRANCE**Function**

Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast

differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity).

Cellular Location

[Isoform 1]: Cell membrane; Single-pass type II membrane protein [Isoform 2]: Cytoplasm.

Tissue Location


Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid

Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) - Images



Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) is more than 97.25%, determined by SEC-HPLC.